

CLAIMS:

- Sub C²*
53. A substantially pure nucleic acid molecule, comprising a sequence of nucleotides encoding an alpha subunit or a beta subunit of a human neuronal nicotinic acetylcholine receptor.
- Sub C²*
54. The molecule of claim 1, wherein the subunit is an alpha2, alpha3 subunit or beta2 subunit.
- Sub C²*
55. A substantially pure subunit of the human neuronal nicotinic acetylcholine receptor encoded by the molecule of claim 1.
- A*
56. A substantially pure subunit of the human neuronal nicotinic acetylcholine receptor encoded by the molecule of claim 2.
57. A nucleic acid molecule that includes a sequence of nucleotides that encodes an alpha or beta subunit of a human neuronal nicotinic acetylcholine receptor and hybridizes under conditions of high stringency to a sequence of nucleotides encoding a subunit of claim 2.
58. The nucleic acid molecule of claim 2, wherein the sequence of nucleotides is selected from a sequence of nucleotides encoding the alpha2 subunit and having the restriction map of the DNA encoding the human alpha2 subunit set forth in Figure 1, a sequence of nucleotides encoding the alpha3 subunit and having the restriction map of the DNA encoding the human alpha3 subunit set forth in Figure 2, or a sequence of nucleotides encoding the beta2 subunit and having the restriction map of the DNA encoding the human beta2 subunit set forth in Figure 3.
- Sub C³*

7/26

59

Isolated cells containing any one or more
of the molecules of claim 1.

60

Isolated cells containing one or more of
the molecules of claim 59.

Subs
82

5

The cells of claim 1 that express a
nicotinic acetylcholine receptor that contains one or
more subunits encoded by said nucleic acid molecule(s).

C

61

The cells of claim 1, wherein said cells are
eukaryotic cells.

A
1
10 subs
X⁴
Cmt

62

The cells of claim 1, wherein said cells
are bacterial cells, mammalian cells, yeast cells or
amphibian oocytes.

15

63

The cells of claim 1, wherein said cells
additionally contain a reporter gene expression
construct; and the reporter gene expression construct
comprises:

20

a transcriptional control element, and
a reporter gene encoding a transcription and/or
translational product;

25

said transcription control element, in said
cell, is responsive to an intracellular condition that
occurs when a human neuronal nicotinic acetylcholine
receptor interacts with a compound having agonist or
antagonist activity with respect to said receptor;

30

said product can be, directly or indirectly,
detected; and

the gene is in operative association with said
transcriptional control element.

65

30

The cells of claim 12, wherein:
the reporter gene expression construct contains
a promoter selected from the group consisting of the
c-fos promoter, the vasoactive intestinal peptide gene

promoter, the somatostatin gene promoter, the proenkephalin gene promoter, the phosphoenolpyruvate carboxykinase gene promoter and the NGFI-A gene promoter, and a reporter gene selected from the group consisting of

5 DNA encoding chloramphenicol transferase (CAT), luciferase, alkaline phosphatase and β -galactosidase; and the promoter is operatively linked to the reporter gene.

D/26 66
10 14. The cells of claim 7, wherein said cells contain nucleic acid encoding an alpha subunit and a beta subunit of a human neuronal nicotinic acetylcholine receptor.

*a!
cont
sub
75*
15 15. *67* The cells of claim 14, wherein said alpha subunit of the human neuronal nicotinic acetylcholine receptor is selected from the human alpha2 subunit or the human alpha3 subunit, and said beta subunit is the human beta2 subunit.

68
20 16. A method for screening compounds for activity as nicotinic acetylcholine receptor agonists or antagonists, comprising determining the effect of the compound on the neuronal nicotinic acetylcholine receptor activity in the cells of claim 67 compared to the effect on control cells or to the effect in the absence of the compound, wherein:

*sub
c4*
25 the activity is assessed by detecting nicotine binding to the cells, measuring the flux of ions through the membranes of the cells, measuring transcription of a reporter gene in the cells, or the electrophysiological response of the cells; and

30 control cells do not express nicotinic acetylcholine receptors.

69 68
17. The method of claim 16, comprising: comparing the difference in the amount of transcription of a reporter gene in the cells in the

presence of the compound with the amount of transcription in the absence of the compound or with the amount of transcription in the control cells that do not express nicotinic acetylcholine receptors, wherein:

- 5 the cells and the control cells contain a reporter gene expression construct;
- the reporter gene expression construct contains a transcriptional control element, and a reporter gene encoding a transcription and/or translational product;
- 10 the transcription control element, in said cell, is responsive to an intracellular condition that occurs when a human neuronal nicotinic acetylcholine receptor interacts with a compound having agonist or antagonist activity with respect to said receptor;
- 15 the product can be, directly or indirectly, detected; and
- the gene is in operative association with said transcriptional control element.

R126 70 68
16. The method of claim 16, wherein the alpha
20 subunit is an alpha₂ subunit encoded by a sequence of nucleotides having the restriction map of the DNA encoding the human alpha₂ subunit set forth in Figure 1 or an alpha₃ subunit encoded by a sequence of nucleotides having the restriction map of the DNA encoding the human alpha₃ subunit set forth in Figure 2, and the beta
25 subunit is encoded by a sequence of nucleotides having the restriction map of the DNA encoding the human beta₂ subunit set forth in Figure 3.

a1 SB H18

71
19. A substantially pure human neuronal
30 nicotinic acetylcholine receptor, comprising at least one human alpha receptor subunit and at least one human beta subunit.

sub 76
20. A method for making cells having neuronal nicotinic acetylcholine receptor activity, comprising:

- (a) introducing one or more nucleic acid molecules of claim 5 that encode(s) at least one alpha subunit of a neuronal nicotinic acetylcholine receptor and at least one beta subunit of a neuronal nicotinic acetylcholine receptor, eukaryotic cells;
- (b) selecting cells from (a) that express the alpha or beta subunit-encoding nucleic acid or express the alpha and beta subunit-encoding nucleic acid; and
- (c) detecting neuronal nicotinic acetylcholine receptor activity in the selected cells, wherein the activity is mediated by a receptor containing one or more of the alpha and beta subunits encoded by said introduced nucleic acid molecules.
- Cont'd*


Applicants respectfully submit that none of these rewritten Claims constitutes new matter.

It is respectfully requested that the Claims fee be computed on the basis of the replacement Claims 1-20 submitted herewith under PCT Article 41 upon entry of this application into the U.S. National phase.

Respectfully submitted,

FITCH, EVEN, TABIN & FLANNERY

By:


Phillip H. Watt
Registration No.: 25,939

Date: Nov. 30, 1992

135 South LaSalle Street
Suite 900
Chicago, Illinois 60603-4277
(312) 372-7842